Evidence map›Paper›PMID 39243754›Full record

ArticleCell reports. Medicine2024

mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity.

Laurie L Kenney, Rebecca Suet-Yan Chiu, Michelle N Dutra, Alexandra Wactor, Chris Honan, Lukas Shelerud, Joshua J Corrigan, Kelly Yu, Joseph D Ferrari, Kate L Jeffrey and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. bioRxiv : the preprint server for biology · 2026
    Article
  8. Review
  9. Review
  10. Clinical Significance of Serum CCR2 and IDO1 in Diabetic Peripheral Neuropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Article
  11. Review
  12. Review
  13. Engineering an indoleamine 2,3-dioxygenase immunotherapyMolecular systems design & engineering · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Laurie L KenneyImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA. Electronic address: laurie.kenney@modernatx.com.
Rebecca Suet-Yan ChiuImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Michelle N DutraImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Alexandra WactorImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Chris HonanImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Lukas ShelerudImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Joshua J CorriganImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Kelly YuImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Joseph D FerrariImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Kate L JeffreyImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.
Eric HuangModerna Genomics, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
Paul L SteinImmune Therapeutic Discovery, Moderna, Inc., 325 Binney Street, Cambridge, MA 02139, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indoleamine-2,3-dioxygenase (IDO)1 degrades tryptophan, obtained through dietary intake, into immunoregulatory metabolites of the kynurenine pathway. Deficiency or blockade of IDO1 results in the enhancement of autoimmune severity in rodent models and increased susceptibility to developing autoimmunity in humans. Despite this, therapeutic modalities that leverage IDO1 for the treatment of autoimmunity remain limited. Here, we use messenger (m)RNA formulated in lipid nanoparticles (LNPs) to deliver a human IDO1 variant containing the myristoylation site of Src to anchor the protein to the inner face of the plasma membrane. This membrane-anchored IDO1 has increased protein production, leading to increased metabolite changes, and ultimately ameliorates disease in three models of T cell-mediated autoimmunity: experimental autoimmune encephalomyelitis (EAE), rat collagen-induced arthritis (CIA), and acute graft-versus-host disease (aGVHD). The efficacy of IDO1 is correlated with hepatic expression and systemic tryptophan depletion. Thus, the delivery of membrane-anchored IDO1 by mRNA suppresses the immune response in several well-characterized models of autoimmunity.

Indexed as

AutoimmunityEncephalomyelitis, Autoimmune, ExperimentalIndoleamine-Pyrrole 2,3,-DioxygenaseRNA, MessengerT-LymphocytesTryptophanAnimalsArthritis, ExperimentalFemaleGraft vs Host DiseaseHumansMiceNanoparticlesRatsIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseRNA, MessengerTryptophanaGVHDautoimmunityCIAEAEIDO1kynurenine pathwaylipid nanoparticlemRNAT cellstryptophan

Identifiers

PMID39243754
PMCPMC11525033

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.